NASDAQ: FBLGFibrobiologics Inc Stock
$11.30+1.06 (+10.35%)
Updated May 14, 2024
FBLG Price
$11.30
Fair Value Price
N/A
Market Cap
$369.73M
52 Week Low
$6.53
52 Week High
$55.00
P/E
N/A
P/B
-95.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-3.95
Operating Cash Flow
N/A
Beta
-3.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FBLG Overview
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FBLG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FBLG's short-term liabilities ($13.99M) exceed its short-term assets ($8.92M)
Short-term Liabilities Financials
FBLG's short-term assets ($8.92M) exceed its long-term liabilities ($1.28M)
Long-term Liabilities Financials
FBLG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more FBLG due diligence checks available for Premium users.
Be the first to know about important FBLG news, forecast changes, insider trades & much more!
FBLG News
Valuation
FBLG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-95.71x
Industry
6.05x
FBLG's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.5M
Profit Margin
0%
Assets to liabilities
Assets
$11.4M
Liabilities
$15.3M
Debt to equity
-3.95
FBLG's short-term liabilities ($13.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FBLG's short-term assets ($8.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FBLG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FBLG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
-$8.0k
Financing
$3.3M
FBLG vs Biotech Stocks
Fibrobiologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.